Does reduced T3 signaling raise LDL cholesterol and apolipoprotein B–containing particles?

Thyroid hormone plays a pivotal role in maintaining lipid homeostasis, directly modulating the clearance of circulating atherogenic lipoproteins through hepatic pathways.

Mechanistic pathways

• Direct transcriptional activation: Triiodothyronine (T3) binds to the hepatic thyroid hormone receptor-beta1 (TRβ1), which heterodimerizes with RXR to target specific thyroid hormone response elements (TREs) within the LDLR promoter, directly inducing LDL receptor (LDLR) gene transcription.
• Indirect pathway amplification: T3 also upregulates the transcription and expression of Sterol Regulatory Element-Binding Protein 2 (SREBP-2). SREBP-2 then binds to sterol regulatory elements (SRE) on the LDLR promoter, further driving hepatic receptor expression.
• Systemic clearance: The resulting increase in hepatic LDLR density accelerates the receptor-mediated endocytosis and catabolism of low-density lipoprotein particles from the systemic circulation.

Clinical consequences of low T3 signaling

• Impaired clearance: In states of reduced T3 signaling, such as overt or subclinical hypothyroidism, hepatic LDLR expression drops significantly, leading to a profound impairment in receptor-mediated clearance.
• Atherogenic particle accumulation: This block in clearance results in elevated circulating LDL cholesterol (LDL-C). Because each low-density, intermediate-density, and very-low-density lipoprotein particle contains a single molecule of apolipoprotein B, reduced T3 signaling simultaneously causes a proportional increase in circulating ApoB-containing particles.
• Therapeutic reversibility: Correcting thyroid hormone deficiency via hormone replacement therapy or utilizing liver-targeted TRβ-selective agonists restores hepatic LDLR expression, successfully clearing circulating cholesterol and reducing ApoB particle counts.

Bottom line

• Reduced T3 signaling downregulates hepatic LDL receptors through both direct TRβ1 binding and indirect SREBP-2 pathways, directly impairing lipoprotein clearance and raising systemic levels of atherogenic LDL-C and apolipoprotein B-containing particles.